Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma

John A. Cox, Shefali R. Gajjar, Thomas B Lanni, Todd Swanson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Acceptable post-orchiectomy adjuvant therapy strategies for stage I seminoma patients include surveillance, para-aortic radiation therapy (RT), dog-leg RT, and a single cycle of carboplatin. The required follow-up recommendations were amended by the National Comprehensive Cancer Network (NCCN) in 2012. Given a cause-specific survival of nearly 100%, a closer analysis of the reimbursement for each treatment strategy is warranted.

Methods: NCCN guidelines were used to design treatment plans for each acceptable adjuvant treatment strategy. Follow-up charges were generated for 10 years based on 2012 (version 1.2012; unchanged in current version 1.2013) and 2011 NCCN (version 2.2011) surveillance recommendations. The 2012 Medicare reimbursement rates were used to calculate each treatment strategy and incremental cost-effectiveness ratios to compare the treatment options.

Results: Under the current NCCN follow-up recommendations, the total reimbursements generated over 10 years of surveillance, para-aortic RT, dog-leg RT, and carboplatin were $10,643, $11,678, $9,662, and $10,405, respectively. This is compared with the reimbursements as per the 2011 NCCN recommendations: $20,986, $11,517, $9,394, and $20,365 respectively. Factoring the rates of relapse into a salvage model, observation was found to be more costly and less effective ($–1,831, $-7,318, $–7,010) in the adjuvant management of stage I seminoma patients.

Conclusion: Based on incremental cost-effectiveness ratios, para-aortic RT, dog-leg RT, and carboplatin are cost-effective options for the treatment of stage I seminoma when compared with observation; however, surveillance could potentially spare as many as 80%–85% of men diagnosed with stage I seminoma from additional therapy after radical inguinal orchiectomy. Such cost and reimbursement analyses are becoming increasingly relevant, but are not meant to usurp sound clinical judgment. Further studies are required to validate these findings.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalResearch and Reports in Urology
Volume7
DOIs
StatePublished - Jan 8 2015

Fingerprint

Seminoma
Costs and Cost Analysis
Radiotherapy
Carboplatin
Leg
Orchiectomy
Dogs
Therapeutics
Neoplasms
Cost-Benefit Analysis
Observation
Groin
Medicare
Guidelines
Recurrence
Survival

Keywords

  • Adjuvant management
  • Cost analysis
  • Low-stage testicular seminoma

ASJC Scopus subject areas

  • Urology

Cite this

Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma. / Cox, John A.; Gajjar, Shefali R.; B Lanni, Thomas; Swanson, Todd.

In: Research and Reports in Urology, Vol. 7, 08.01.2015, p. 1-7.

Research output: Contribution to journalArticle

@article{e481ecba0b08494282e684c3456033b3,
title = "Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma",
abstract = "Background: Acceptable post-orchiectomy adjuvant therapy strategies for stage I seminoma patients include surveillance, para-aortic radiation therapy (RT), dog-leg RT, and a single cycle of carboplatin. The required follow-up recommendations were amended by the National Comprehensive Cancer Network (NCCN) in 2012. Given a cause-specific survival of nearly 100{\%}, a closer analysis of the reimbursement for each treatment strategy is warranted.Methods: NCCN guidelines were used to design treatment plans for each acceptable adjuvant treatment strategy. Follow-up charges were generated for 10 years based on 2012 (version 1.2012; unchanged in current version 1.2013) and 2011 NCCN (version 2.2011) surveillance recommendations. The 2012 Medicare reimbursement rates were used to calculate each treatment strategy and incremental cost-effectiveness ratios to compare the treatment options.Results: Under the current NCCN follow-up recommendations, the total reimbursements generated over 10 years of surveillance, para-aortic RT, dog-leg RT, and carboplatin were $10,643, $11,678, $9,662, and $10,405, respectively. This is compared with the reimbursements as per the 2011 NCCN recommendations: $20,986, $11,517, $9,394, and $20,365 respectively. Factoring the rates of relapse into a salvage model, observation was found to be more costly and less effective ($–1,831, $-7,318, $–7,010) in the adjuvant management of stage I seminoma patients.Conclusion: Based on incremental cost-effectiveness ratios, para-aortic RT, dog-leg RT, and carboplatin are cost-effective options for the treatment of stage I seminoma when compared with observation; however, surveillance could potentially spare as many as 80{\%}–85{\%} of men diagnosed with stage I seminoma from additional therapy after radical inguinal orchiectomy. Such cost and reimbursement analyses are becoming increasingly relevant, but are not meant to usurp sound clinical judgment. Further studies are required to validate these findings.",
keywords = "Adjuvant management, Cost analysis, Low-stage testicular seminoma",
author = "Cox, {John A.} and Gajjar, {Shefali R.} and {B Lanni}, Thomas and Todd Swanson",
year = "2015",
month = "1",
day = "8",
doi = "10.2147/RRU.S74125",
language = "English (US)",
volume = "7",
pages = "1--7",
journal = "Research and Reports in Urology",
issn = "1179-1551",
publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma

AU - Cox, John A.

AU - Gajjar, Shefali R.

AU - B Lanni, Thomas

AU - Swanson, Todd

PY - 2015/1/8

Y1 - 2015/1/8

N2 - Background: Acceptable post-orchiectomy adjuvant therapy strategies for stage I seminoma patients include surveillance, para-aortic radiation therapy (RT), dog-leg RT, and a single cycle of carboplatin. The required follow-up recommendations were amended by the National Comprehensive Cancer Network (NCCN) in 2012. Given a cause-specific survival of nearly 100%, a closer analysis of the reimbursement for each treatment strategy is warranted.Methods: NCCN guidelines were used to design treatment plans for each acceptable adjuvant treatment strategy. Follow-up charges were generated for 10 years based on 2012 (version 1.2012; unchanged in current version 1.2013) and 2011 NCCN (version 2.2011) surveillance recommendations. The 2012 Medicare reimbursement rates were used to calculate each treatment strategy and incremental cost-effectiveness ratios to compare the treatment options.Results: Under the current NCCN follow-up recommendations, the total reimbursements generated over 10 years of surveillance, para-aortic RT, dog-leg RT, and carboplatin were $10,643, $11,678, $9,662, and $10,405, respectively. This is compared with the reimbursements as per the 2011 NCCN recommendations: $20,986, $11,517, $9,394, and $20,365 respectively. Factoring the rates of relapse into a salvage model, observation was found to be more costly and less effective ($–1,831, $-7,318, $–7,010) in the adjuvant management of stage I seminoma patients.Conclusion: Based on incremental cost-effectiveness ratios, para-aortic RT, dog-leg RT, and carboplatin are cost-effective options for the treatment of stage I seminoma when compared with observation; however, surveillance could potentially spare as many as 80%–85% of men diagnosed with stage I seminoma from additional therapy after radical inguinal orchiectomy. Such cost and reimbursement analyses are becoming increasingly relevant, but are not meant to usurp sound clinical judgment. Further studies are required to validate these findings.

AB - Background: Acceptable post-orchiectomy adjuvant therapy strategies for stage I seminoma patients include surveillance, para-aortic radiation therapy (RT), dog-leg RT, and a single cycle of carboplatin. The required follow-up recommendations were amended by the National Comprehensive Cancer Network (NCCN) in 2012. Given a cause-specific survival of nearly 100%, a closer analysis of the reimbursement for each treatment strategy is warranted.Methods: NCCN guidelines were used to design treatment plans for each acceptable adjuvant treatment strategy. Follow-up charges were generated for 10 years based on 2012 (version 1.2012; unchanged in current version 1.2013) and 2011 NCCN (version 2.2011) surveillance recommendations. The 2012 Medicare reimbursement rates were used to calculate each treatment strategy and incremental cost-effectiveness ratios to compare the treatment options.Results: Under the current NCCN follow-up recommendations, the total reimbursements generated over 10 years of surveillance, para-aortic RT, dog-leg RT, and carboplatin were $10,643, $11,678, $9,662, and $10,405, respectively. This is compared with the reimbursements as per the 2011 NCCN recommendations: $20,986, $11,517, $9,394, and $20,365 respectively. Factoring the rates of relapse into a salvage model, observation was found to be more costly and less effective ($–1,831, $-7,318, $–7,010) in the adjuvant management of stage I seminoma patients.Conclusion: Based on incremental cost-effectiveness ratios, para-aortic RT, dog-leg RT, and carboplatin are cost-effective options for the treatment of stage I seminoma when compared with observation; however, surveillance could potentially spare as many as 80%–85% of men diagnosed with stage I seminoma from additional therapy after radical inguinal orchiectomy. Such cost and reimbursement analyses are becoming increasingly relevant, but are not meant to usurp sound clinical judgment. Further studies are required to validate these findings.

KW - Adjuvant management

KW - Cost analysis

KW - Low-stage testicular seminoma

UR - http://www.scopus.com/inward/record.url?scp=84920996703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920996703&partnerID=8YFLogxK

U2 - 10.2147/RRU.S74125

DO - 10.2147/RRU.S74125

M3 - Article

AN - SCOPUS:84920996703

VL - 7

SP - 1

EP - 7

JO - Research and Reports in Urology

JF - Research and Reports in Urology

SN - 1179-1551

ER -